Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2019

Open Access 01-06-2019 | Review Article

The dual effect of morphine on tumor development

Authors: H. Tuerxun, J. Cui

Published in: Clinical and Translational Oncology | Issue 6/2019

Login to get access

Abstract

Morphine is a classic opioid drug used for reducing pain and is commonly prescribed as an effective drug to control cancer pain. Morphine has a direct role in the central nervous system to relieve pain, but because of its peripheral functions, morphine also has some side effects, such as nausea, constipation, and addiction (Gupta et al. in Sci World J 2015:10, 2015). In addition to its analgesic effect, the role of morphine in tumor development is an important question that has been investigated for many years with conflicting results. Numerous studies suggest that morphine has a role in both promoting and inhibiting tumor growth. In this extensive review, we attempt to comprehensively understand the effects of morphine and summarize both its positive and negative influences on various aspects of tumors, including tumor growth, angiogenesis, metastasis, inflammation, and immunomodulation.
Literature
1.
Gupta M, Msambichaka L, Ballas SK, Gupta K. Morphine for the treatment of pain in sickle cell disease. Sci World J. 2015;2015:10.CrossRef
2.
Shen LD, Yang J, Li YX, et al. Correlation between senile cancer pain and depression and its effect on immune function[J]. J Kunming Med Coll. 2011;2(3):31–4.
3.
Grace Peter M, Maier Steven F, Watkins Linda R. Opioid-induced central immune signaling: implications for opioid analgesia. Headache. 2015;55(4):475–89.CrossRef
4.
Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, Niederberger E, Scholich K, Geisslinger G. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cell:involvement of p53 phosphorylation. Cancer Res. 2003;63(8):1846–52.PubMed
5.
Gonzalez-Nunez Veronica, Noriega-Prieto Jose Antonio, Rodríguez Raquel E. Morphine modulates cell proliferation through mir133b & mir128 in the neuroblastoma SH-SY5Y cell line. Biochim Biophys Acta Mol Basis Dis. 2014;1842(4):566–72.CrossRef
6.
Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol. 1996;296(2):199–207.CrossRef
7.
Lin X, Wang YJ, Li Q, Hou YY, Hong MH, Cao YL, Chi ZQ, Liu JG. Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J. 2009;276(7):2022–36.CrossRef
8.
Yin D, Mufson RA, Wang R, Shi Y. Fas-mediated cell death promoted by opioids. Nature. 1999;397(6716):218.CrossRef
9.
Pati ML, Hornick JR, Niso M, Berardi F, Spitzer D. Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer. BMC Cancer. 2017;17(1):51.CrossRef
10.
Diao CT, Li L, Lau SY, Wong TM, Wong NS. kappa-Opioid receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 humanepithelial tumor cell line. Biochim Biophys Acta. 2000;1499(1–2):49–62.CrossRef
11.
Hatsukari Ikusuke, Hitosugi Naoko, Ohno Rie, Hashimoto Ken, Nakamura Shinichi, Satoh Kazue, Nagasaka Hiroshi, Matsumoto Isao, Sakagami Hiroshi. Induction of apoptosis by morphine in human tumor cell lines in vitro. Anticancer Res. 2007;27(2):857–64.PubMed
12.
Sergeeva MG, Grishina ZV, Varfolomeyev SD. Morphine effect on proliferation of normal and tumor cells of immune origin. Immunol Lett. 1993;36(2):215–8.CrossRef
13.
Bimonte Sabrina, Barbieri Antonio, Rea Domenica, Palma Giuseppe, Luciano Antonio, Cuomo Arturo, Arra Claudio, Izzo Francesco. Morphine Promotes Tumor Angiogenesis and Increases Breast Cancer Progression. Biomed Res Int. 2015;2015:161508.PubMedPubMedCentral
14.
Cao LH, Li HT, Lin WQ, et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6:18706.CrossRef
15.
Mathew B, Lennon FE, Siegler J, Mambetsariev N, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2011;112(3):558–67.CrossRef
16.
Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson K, Gupta V, Kratzke R, Kalpna G. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cell. Anesth Analg. 2011;113(6):1353–64.CrossRef
17.
Vincent L, Vang D, Nguyen J, et al. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood. 2013;122:1853–62.CrossRef
18.
Aich A, Afrin LB, Gupta K. Mast cell-mediated mechanisms of nociception. Int J Mol Sci. 2015;16:29069–92.CrossRef
19.
Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides. 2013;48:1–9.CrossRef
20.
Lin X, Li Q, Wang YJ, Ju YW, Chi ZQ, Wang MW, Liu JG. Morphine inhibits doxorubicin-induced reactive oxygen species generation and nuclear factor kappaB transcriptional activation in neuroblastoma SH-SY5Y cells. Biochem J. 2007;406(2):215–21.CrossRef
21.
Ma Y, Ren Z, Ma S, Yan W, He M, Wang D, Ding P. Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. Ren Fail. 2017;39(1):258–64.CrossRef
22.
Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153–5.CrossRef
23.
Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2001;21(6b):4221–9.PubMed
24.
Balasubramanian S, Ramakrishnan S, Charboneau R, Wang J, Barke RA, Roy S. Morphine sulfate inhibits hypoxia-induced vascular endothelial growth factor expression in endothelial cells and cardiac myocytes. J Mol Cell Cardiol. 2001;33:2179–87.CrossRef
25.
Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol. 2010;177(2):984–97.CrossRef
26.
Yamamizu K, Hamada Y, Narita M. j Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol. 2015;172(2):268–76.CrossRef
27.
Koodie L, Yuan H, Pumper JA, et al. Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol. 2014;184:1073–84.CrossRef
28.
Singleton PA, Moss J. Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010;6(8):1237–42.CrossRef
29.
Kevil CG, Orr AW, Langston W, Mickett K, Murphy-Ullrich J, Patel RP, et al. Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. J Biol Chem. 2004;279(18):19230–8.CrossRef
30.
31.
Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97(11):1523–31.CrossRef
32.
Yamamoto Kazuhiro, Murphy Gillian, Troeberg Linda. Extracellular regulation of metalloproteinases. Matrix Biol. 2015;44–46:255–63.CrossRef
33.
Gouri Adel, Dekaken Aoulia, El Bairi Khalid, Aissaoui Arifa, Laabed Nihad, Chefrour Mohamed, Ciccolini Joseph, Milano Gérard, Benharkat Sadek. Plasminogen activator system and breast cancer: potential role in therapy decision making and precision medicine. Biomarker Insight. 2016;11:105–11.CrossRef
34.
Xie Nan, Khabbazi Samira, Nassar Zeyad D, Gregory Kye, Vithanage Tharindu, Anand-Apte Bela, Cabot Peter J, Sturgess David, Shaw Paul N, Parat Marie-Odile. Morphine alters the circulating proteolytic profile in mice: functional consequences on cellular migration and invasion. FASEB J. 2017;31(12):5208–16.CrossRef
35.
Gach Katarzyna, Szemraj Janusz, Wyrębska Anna, Janecka Anna. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep. 2011;38(2):1231–6.CrossRef
36.
Min Too Jae, Park Sang-Hee, Ji Yi-Hwa, Lee Yoon-Sook, Kim Tae Woo, Kim Jae Hwan, Kim Woon-Young, Park Young-Cheol. Morphine attenuates endothelial cell adhesion molecules induced by the supernatant of LPS-stimulated colon cancer cells. J Korean Med Sci. 2011;26(6):747–52.CrossRef
37.
Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des. 2009;74(4):390–6.CrossRef
38.
Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro DS. Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci. 2008;53(2):461–6.CrossRef
39.
Liu S, Qi L, Yu Q, et al. Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma. Tumour Biol. 2014;35:8281–8.CrossRef
40.
Chen X, Chen XG, Hu X, et al. MiR-34a and miR-203 inhibit survivin expression to control cell proliferation and survival in human osteosarcoma cells. J Cancer. 2016;7:1057–65.CrossRef
41.
Boettger MK, Weber K, Gajda M, Brauer R, Schaible HG. Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis. Brain Behav Immun. 2010;24(3):474–85.CrossRef
42.
Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, Loeffler JP, Stein C. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest. 1997;100(1):142–8.CrossRef
43.
Finley MJ, Happel CM, Kaminsky DE, Rogers TJ. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol. 2008;252(1–2):146–54.CrossRef
44.
Sabita R, Jinghua W, Jennifer K, Lisa K, Josephine M. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmun Pharmacol. 2006;1:77–89.CrossRef
45.
Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol. 2006;1:77–89.CrossRef
46.
Grimm MC, Ben-Baruch A, Taub DD, Howard OM, Resau JH, Wang JM, Ali H, Richardson R, Snyderman R, Oppenheim JJ. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med. 1998;188:317–25.CrossRef
47.
Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45:9–24.CrossRef
48.
Menzebach A, Hirsch J, Nost R, Mogk M, Hempelmann G, Welters ID. Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide dependent mechanism. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004;39:204–11.CrossRef
49.
Tabellini G, Borsani E, Benassi M, et al. Effects of opioid therapy on human natural killer cells. Int Immunopharmacol. 2014;18:169–74.CrossRef
50.
Ninković Jana, Roy Sabita. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45(1):9–24.CrossRef
51.
Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. Pain control in inflammation governed by selectins. Nat Med. 1998;4:1425–8.CrossRef
52.
Roy S, Chapin RB, Cain KJ, Charboneau RG, Ramakrishnan S, Barke RA. Morphine inhibits transcriptional activation of IL-2 in mouse thymocytes. Cell Immunol. 1997;179:1–9.CrossRef
53.
Liang Xuan, Liu Renyu, Chen Chunhua, Ji Fang, Li Tianzuo. Opioid system modulates the immune function: a review. Trans Perioperat Pain Med. 2016;1(1):5–13.
54.
Weber RJ, Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science. 1989;245:188–90.CrossRef
55.
Irwin M, Hauger RL, Brown M, Britton KT. CRF activates autonomic nervous system and reduces natural killer cytotoxicity. Am J Physiol. 1988;255(5 Pt 2):R744–7.PubMed
56.
Hernandez MC, Flores LR, Bayer BM. Immunosuppression by morphine is mediated by central pathways. J Pharmacol Exp Ther. 1993;267:1336–41.PubMed
57.
Saurer TB, Ijames SG, Lysle DT. Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity. J Neuroimmunol. 2006;177:18–26.CrossRef
58.
Fecho K, Maslonek KA, Dykstra LA, Lysle DT. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J Pharmacol Exp Ther. 1996;277:633–45.PubMed
59.
Mellon RD, Bayer BM. Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res. 1998;789:56–67.CrossRef
60.
Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119:4103–10.CrossRef
61.
Zylla D, Ma Kuskowski, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:1–8.CrossRef
Metadata
Title
The dual effect of morphine on tumor development
Authors
H. Tuerxun
J. Cui
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1974-5

Other articles of this Issue 6/2019

Clinical and Translational Oncology 6/2019 Go to the issue

Research Article

Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes

Correction

Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)

Research Article

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

Research Article

The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial

Review Article

Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives

Brief Research Article

Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits